A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST) KEAP1/NRF2 and LKB1 Aberrant Tumors | NYU Langone Health

Go Back to All Clinical Trials

A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST) KEAP1/NRF2 and LKB1 Aberrant Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Nf1 Aberrations, Nf1 Mutant Malignant Peripheral Nerve Sheath Tumors (mpnst), Keap1/nrf2 And Lkb1 Aberrant Tumors
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Patients must have histologically confirmed malignancy that is metastatic or unresectable. 3.1.2 Patient must have histopathologic confirmation of advanced solid tumor with NF1 mutation, NF1 mutant MPNST, KEAP1/NRF2 mutant and STK11/LKB1 mutant tumors by genetic sequencing. 2) Patient must have exhausted all available standard therapies .

You may not be eligible for this study if the following are true:

1) Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. 2) Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1). 3) Patients who are receiving any other investigational agents.